All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Editorial: Heterogeneity and plasticity of prostate cancer

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F23%3A00574523" target="_blank" >RIV/68081707:_____/23:00574523 - isvavai.cz</a>

  • Result on the web

    <a href="https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1228126/full" target="_blank" >https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1228126/full</a>

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    Editorial: Heterogeneity and plasticity of prostate cancer

  • Original language description

    Prostate cancer represents a highly heterogeneous and one of the most clinically common malignancies in men. Despite the improvement in the management of localized prostate cancer, therapy options for the advanced stages of the disease remain limited. Resistance to endocrine and chemotherapy treatments in prostate cancer is a subject of ongoing discussion and investigation. Limited understanding of the extent of cellular plasticity, clonality and intratumoral heterogeneity in the context of therapy resistance remains one of the main bottlenecks of current prostate cancer research. There is an increased number of novel drugs available. However, the mechanisms that are relevant to therapy resistance are incompletely understood and additional studies are needed. The ultimate goal may be to establish evidence-based drug sequences on the basis of understanding the action of transcription factors, oncogenic and tumor-suppressive miRNA in prostate cancer. Another challenge for experimental therapy is the existence of stem cells which may be targeted by some drugs originally implemented in non-malignant diseases.

  • Czech name

  • Czech description

Classification

  • Type

    O - Miscellaneous

  • CEP classification

  • OECD FORD branch

    10608 - Biochemistry and molecular biology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2023

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů